» Articles » PMID: 39672637

The Contemporary Spectrum of Radiotherapy for Hematologic Malignancies Involving the Central Nervous System: From Focal Therapy to Craniospinal

Overview
Specialties Oncology
Radiology
Date 2024 Dec 13
PMID 39672637
Authors
Affiliations
Soon will be listed here.
Abstract

The contemporary landscape of systemic therapy options for hematologic malignancies involving the central nervous system (CNS-HM) is rapidly evolving; a key question is how radiotherapy (RT) can be optimally integrated to improve patient outcomes. Historically, use of RT to treat CNS-HM was defined by broad fields and high doses. While effective, this approach raised concerns of potential neurotoxicity which significantly decreased RT utilization. RT was replaced by high-dose, CNS-penetrant, systemic therapies that offered durable control with lower perceived neurotoxic risk. But, as the therapeutic toolbox for CNS-HM expands, so too does the complexity and diversity of potential clinical scenarios where RT should be considered. In this review, we describe both well-established and emerging opportunities for RT integration, emphasizing how dose selection and field design could balance neurotoxicity risk and disease control. We propose an anatomical framework that captures the diverse utilization of RT for CNS-HM and serves as a practical guide for RT volume and dose design.

References
1.
Gavrilovic I, Hormigo A, Yahalom J, DeAngelis L, Abrey L . Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006; 24(28):4570-4. DOI: 10.1200/JCO.2006.06.6910. View

2.
Cederquist G, Schefflein J, Devlin S, Shah G, Shouval R, Hubbeling H . CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomas. Blood Adv. 2024; 8(19):5192-5199. PMC: 11530392. DOI: 10.1182/bloodadvances.2024013393. View

3.
Bhojwani D, Sabin N, Pei D, Yang J, Khan R, Panetta J . Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(9):949-59. PMC: 3948096. DOI: 10.1200/JCO.2013.53.0808. View

4.
Ferreri A, Blay J, Reni M, Pasini F, Spina M, Ambrosetti A . Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003; 21(2):266-72. DOI: 10.1200/JCO.2003.09.139. View

5.
Pinnix C, Yahalom J, Specht L, Shbib Dabaja B . Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018; 102(1):53-58. DOI: 10.1016/j.ijrobp.2018.05.067. View